

Cem Akin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/622797/publications.pdf>

Version: 2024-02-01

107
papers

7,923
citations

81889

39
h-index

49904

87
g-index

127
all docs

127
docs citations

127
times ranked

3888
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.8	1,020
2	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood</i> , 2017, 129, 1420-1427.	1.4	520
3	The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. <i>Blood</i> , 2002, 99, 1741-1744.	1.4	416
4	Mast Cells, Mastocytosis, and Related Disorders. <i>New England Journal of Medicine</i> , 2015, 373, 163-172.	27.0	402
5	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2530-2541.	27.0	383
6	A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. <i>Blood</i> , 2004, 103, 3222-3225.	1.4	336
7	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	2.9	289
8	Mast cell activation syndrome: Proposed diagnostic criteria. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1099-1104.e4.	2.9	266
9	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. <i>Leukemia Research</i> , 2003, 27, 635-641.	0.8	217
10	Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. <i>Experimental Hematology</i> , 2003, 31, 686-692.	0.4	213
11	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.9	210
12	Diagnosis and treatment of systemic mastocytosis: state of the art. <i>British Journal of Haematology</i> , 2003, 122, 695-717.	2.5	187
13	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3546-3567.	3.8	152
14	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	3.8	150
15	17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. <i>Blood</i> , 2004, 103, 1078-1084.	1.4	147
16	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
17	Mast cell activation syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 349-355.	2.9	140
18	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	2.7	128

#	ARTICLE	IF	CITATIONS
19	Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. <i>World Allergy Organization Journal</i> , 2016, 9, 7.	3.5	124
20	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
21	Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. <i>Leukemia Research</i> , 2011, 35, 1143-1152.	0.8	111
22	The Mastocytosis Society Survey on Mast Cell Disorders: Patient Experiences and Perceptions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 70-76.	3.8	107
23	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	10.0	107
24	How I treat patients with advanced systemic mastocytosis. <i>Blood</i> , 2010, 116, 5812-5817.	1.4	106
25	Diagnostic Criteria and Classification of Mastocytosis in 2014. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 207-218.	1.9	89
26	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 44-51.	2.1	87
27	Molecular Diagnosis of Mast Cell Disorders. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 412-419.	2.8	79
28	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
29	AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 883-896.	2.9	72
30	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. <i>European Journal of Haematology</i> , 2015, 94, 474-490.	2.2	64
31	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2976.	4.1	64
32	Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1248-1255.	3.8	61
33	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016, 101, 1133-1143.	3.5	60
34	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9030.	4.1	56
35	Treatment Strategies in Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 433-447.	1.9	53
36	Clonality and Molecular Pathogenesis of Mastocytosis. <i>Acta Haematologica</i> , 2005, 114, 61-69.	1.4	52

#	ARTICLE	IF	CITATIONS
37	Anaphylaxis and Mast Cell Disease: What Is the Risk?. <i>Current Allergy and Asthma Reports</i> , 2010, 10, 34-38.	5.3	48
38	Mast Cell Activation Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 252-257.e1.	3.8	45
39	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 356-366.e4.	2.9	42
40	Hereditary alpha tryptasemia is not associated with specific clinical phenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 728-735.e2.	2.9	42
41	Anaphylaxis After Hymenoptera Sting: Is It Venom Allergy, a Clonal Disorder, or Both?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 350-355.	3.8	40
42	Mast Cell Activation Syndromes Presenting as Anaphylaxis. <i>Immunology and Allergy Clinics of North America</i> , 2015, 35, 277-285.	1.9	36
43	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	3.8	35
44	Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1109-1114.	3.8	34
45	Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1497-1501.e1.	2.9	34
46	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928.	3.8	33
47	Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 169-177.	5.7	32
48	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2139-2144.	3.8	31
49	Endocrine manifestations of systemic mastocytosis in bone. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016, 17, 419-431.	5.7	30
50	Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment. <i>Current Allergy and Asthma Reports</i> , 2006, 6, 282-288.	5.3	27
51	Mast cell activation syndrome: Importance of consensus criteria and call for research. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1008-1010.	2.9	27
52	Anaphylaxis and Mast Cell Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 45-63.	1.9	27
53	Idiopathic anaphylaxis yardstick. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 16-27.	1.0	26
54	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25

#	ARTICLE	IF	CITATIONS
55	High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1197-1199.	2.9	24
56	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	6.1	24
57	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	2.9	23
58	Idiopathic Anaphylaxis: a Perplexing Diagnostic Challenge for Allergists. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 11.	5.3	20
59	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963.	3.8	20
60	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012, 120, 799-799.	1.4	19
61	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1855-1865.	2.9	19
62	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018, 103, 1760-1771.	3.5	18
63	Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3198-3199.	3.8	18
64	Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1866-1874.	2.9	18
65	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (lâ€¢CBF) Tj ETQq1 1 0.784314 rgBT	2.8	17
66	Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1912-1918.	2.9	17
67	The Mastocytosis Society Survey on Mast Cell Disorders: Part 2â€¢Patient Clinical Experiences and Beyond. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1157-1165.e6.	3.8	16
68	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2083-2086.	3.8	16
69	Management of Mastocytosis in Pregnancy: A Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1217-1223.	3.8	15
70	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014, 124, 636-636.	1.4	15
71	Cladribine for mastocytosis: benefits and risks. <i>Blood</i> , 2015, 126, 931-932.	1.4	14
72	Prevalence of mastocytosis and Hymenoptera venom allergy in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1316-1323.	2.9	12

#	ARTICLE	IF	CITATIONS
73	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020, 61, 1075-1083.	1.3	11
74	BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant.. <i>Blood</i> , 2004, 104, 797-797.	1.4	11
75	Diffuse cutaneous mastocytosis with novel somatic <scp>KIT</scp> mutation K509I and association with tuberous sclerosis. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1834-1840.	0.5	9
76	New Insights into Clonal Mast Cell Disorders Including Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 341-350.	1.9	9
77	Mast Cell Activation. <i>Medical Clinics of North America</i> , 2020, 104, 177-187.	2.5	9
78	Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1196-1201.	3.8	9
79	Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: AAWork Group Report of the AAAAI Allergic Skin Diseases Committee. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 964-983.	2.9	9
80	Hymenoptera-induced anaphylaxis: is it a mast cell driven hematological disorder?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 356-362.	2.3	8
81	Blisters, Vaccines, and Mast Cells: A Difficult Case of Diffuse Cutaneous Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1370-1372.	3.8	8
82	A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1454.	4.1	8
83	Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 414.	2.7	8
84	Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?. <i>European Journal of Haematology</i> , 2016, 96, 655-657.	2.2	7
85	Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. <i>Blood Reviews</i> , 2021, 45, 100693.	5.7	7
86	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 487-498.	3.1	7
87	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
88	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013, 122, 106-106.	1.4	6
89	Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 434.	2.7	5
90	Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, xvii-xviii.	1.9	4

#	ARTICLE	IF	CITATIONS
91	Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis. Current Treatment Options in Allergy, 2014, 1, 247-261.	2.2	4
92	Phase II Study of Dasatinib (SPRYCEL®,) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.. Blood, 2007, 110, 3551-3551.	1.4	4
93	The Role of KIT Mutations in Anaphylaxis. Current Allergy and Asthma Reports, 2019, 19, 31.	5.3	3
94	Recent advances in mast cell clonality and anaphylaxis. F1000 Medicine Reports, 2009, 1, .	2.9	3
95	Finding the right KIT inhibitor for advanced systemic mastocytosis. Nature Medicine, 2021, 27, 2081-2082.	30.7	3
96	Mast Cell Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 557-558.	3.8	2
97	Accurate Diagnosis and Prognosis in Systemic Mastocytosis: The Role of Mutational Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3128-3129.	3.8	1
98	Itching Without a Rash. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 307-308.	3.8	0
99	Tryptase Increase without Mastocytosis or Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 869.	3.8	0
100	Toward a Unified Database Registry in Mastocytosis. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 88.	3.8	0
101	Reply. Journal of Allergy and Clinical Immunology, 2021, 148, 1343-1344.	2.9	0
102	Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFRA-Associated Hypereosinophilic Syndrome.. Blood, 2006, 108, 2683-2683.	1.4	0
103	Novel C-KIT Transcripts Identified in Mast Cell Leukemia: An Update of the Full Transcript and Its™s Distribution.. Blood, 2007, 110, 2396-2396.	1.4	0
104	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	1.4	0
105	Scratching the Itch: Managing Recurrent Pruritic Skin Conditions. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 882-883.e15.	3.8	0
106	Remission of indolent systemic mastocytosis in the absence of targeted therapy. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	0
107	Reply to “Need to define a subgroup of patients with idiopathic mast cell activation syndrome”. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1128.	3.8	0